激光介导的透皮给药技术用于血管瘤治疗的研究

Research on Laser Mediated Transdermal Drug Delivery Technology for the Treatment of Hemangioma

目的探讨分析激光介导的透皮给药技术用于血管瘤治疗的研究。方法收集自2021年7月至2023年2月期间在江西省妇幼保健院医学美容科接受完整疗程治疗的体表增生期血管瘤婴幼儿病历资料做回顾性研究,从超脉冲CO_(2)激光介导透皮给药技术后外敷马来酸噻吗洛尔滴眼液治疗组中抽取50例作为试验组,从点阵CO_(2)激光介导透皮给药技术后外敷马来酸噻吗洛尔滴眼液治疗组中抽取50例作为对照组1,从直接外敷马来酸噻吗洛尔滴眼液治疗组中抽取50例作为对照组2。结果试验组治愈25例、显效19例、无效6例;对照组1治愈20例、显效16例、无效14例;对照组2治愈18例、显效16例、无效16例。比较三组治疗方案的疗效数据行卡方检验,(P<0.05),差异具有统计学意义,试验组治疗疗效最高,(P<0.05),差异有统计学意义。本研究中试验组治疗需(2.92±1.412)疗程;对照组1治疗需(3.96±1.551)疗程;对照组2治疗需(4.18±1.466)疗程;治疗所需疗程相关数据进行方差分析,(P<0.05),差异具有统计学意义,试验组的疗程最短,(P<0.05),差异具有统计学意义。结论将超脉冲CO_(2)激光介导的透皮给药技术应用于马来酸噻吗洛尔在婴幼儿体表增生期血管瘤的治疗中可有效提高临床疗效,缩短疗程。

Objective To explore and analyze the application of laser mediated transdermal drug delivery technology in the treatment of vascular tumors.Methods A retrospective study was conducted on the medical records of infants and young children with proliferative hemangioma who received a complete course of treatment at the Medical Aesthetics Department of Jiangxi Maternal and Child Health Hospital from July 2021 to February 2023.Fifty cases were selected as the experimental group from the group treated with ultra pulse CO_(2)laser mediated transdermal delivery technology and external application of thiamol maleate eye drops.Fifty cases were selected as the control group 1 from the group treated with lattice CO_(2)laser mediated transdermal delivery technology and external application of thiamol maleate eye drops.Fifty cases were selected as the control group 2 from the group treated with direct external application of thiamol maleate eye drops.Results In the experimental group,25 cases were cured,19 cases showed signifificant improvement,and 6 cases were ineffective;Control group 1:20 cases were cured,16 cases were signifificantly improved,and 14 cases were ineffective;In control group 2,18 cases were cured,16 cases were signifificantly improved,and 16 cases were ineffective.The effificacy data of three treatment plans were compared using chi square test(P<0.05),and the difference was statistically signifificant.The experimental group had the highest treatment effificacy(P<0.05),and the difference was statistically signifificant.In this study,the experimental group required(2.92±1.412)course of treatment;Control group 1 requires(3.96±1.551)course of treatment;Control group 2 requires(4.18±1.466)course of treatment;Analysis of variance(P<0.05)was performed on the data related to the required course of treatment,and the difference was statistically signifificant.The experimental group had the shortest course of treatment(P<0.05),and the difference was statistically signifificant.Conclusion The application of transdermal drug delivery technology mediated by ultra pulsed CO_(2)laser to the treatment of timolol maleate in infants and young children with proliferative hemangioma can effectively improve clinical effificacy and shorten the course of treatment.